About 14 results found for searched term "VEGFR2-IN-4" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43537 | TIE-2/VEGFR-2 kinase-IN-4 | VEGFR/PDGFR |
| TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. | ||
| M43544 | hCA/VEGFR-2-IN-4 | VEGFR/PDGFR |
| hCA/VEGFR-2-IN-4 is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. | ||
| M43548 | VEGFR2-IN-4 | VEGFR/PDGFR |
| VEGFR2-IN-4 is a potent and selective VEGFR2 kinase inhibitor, with a GI50 of 0.7 nM. | ||
| M1656 | Tivozanib (AV-951) | VEGFR/PDGFR |
| KRN951; Tivozanib | ||
| AV-951 (Tivozanib) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. | ||
| M1964 | Vandetanib | VEGFR/PDGFR |
| ZD6474, Zactima | ||
| Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase (IC50=40 nM). Vandetanib also inhibited VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM). | ||
| M4894 | Cabozantinib malate | VEGFR/PDGFR |
| XL184;Cabozantinib S-malate | ||
| Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. | ||
| M8758 | GW806742X | Necroptosis |
| GW806742X is an ATP site-targeing kinase inhibitor (IC50 in nM = 2/VEGFR2, 15/SRC, 47/C-FMS, 851/GSK3, 9016/ERBB2, 9120/FGFR) with potent antiproliferation activity against cancer cultures (IC50 in nM = 5/HUVEC-v, 424/HUVEC-b, 81/HEF, 453/MDA468, 470/A375P, 693/HT29, 734/PC3), GW806742X is now better known as Compound 1 for its anti-necroptosis activity via affinity interaction with ML | ||
| M9540 | ODM-203 | VEGFR/PDGFR |
| ODM203 | ||
| ODM-203 is an orally available inhibitor of VEGFR and FGFR, with IC50s of 26, 9, 5 nM for VEGFR1, VEGFR2 and VEGFR3, and 11, 16, 6, 35 nM for recombinant FGFR1, FGFR2, FGFR3 and FGFR4, respectively. | ||
| M14921 | Telatinib mesylate | VEGFR/PDGFR |
| Bay 57-9352 mesylate | ||
| Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively. | ||
| M20715 | CS-2660 (JNJ-38158471) | VEGFR/PDGFR |
| CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM，while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. | ||
| M25278 | Pegdinetanib | VEGFR/PDGFR |
| BMS-844203; CT-322 | ||
| Pegdinetanib (BMS-844203; CT-322) is a selective VEGFR-2 (VEGFR) inhibitor with Kds of 11 nM and 250 nM and IC50s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity. | ||
| M29047 | YF-452 | VEGFR/PDGFR |
| YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research. | ||
| M42295 | hCA/VEGFR-2-IN-1 | Carbonic Anhydrase |
| hCA/VEGFR-2-IN-1 is a potent dual Carbonic Anhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. | ||
| M43551 | VEGFR-2-IN-33 | VEGFR/PDGFR |
| VEGFR-2-IN-33 is a VEGFR inhibitor (IC50: 61.04 nM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
